A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs KX 01 (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors Athenex
- 28 Nov 2017 According to an Athenex medis release, data will be presented at the American Academy of Dermatology Annual Meeting.
- 09 Nov 2017 According to an Athenex media release, data release from this trial is expected in 4th quarter of 2017.
- 14 Aug 2017 According to Athenex Inc.media release, data release from this trial is expected in second half of 2017.